LELAND, N.C., July 30, 2025 /PRNewswire/ -- Flow Sciences, a global leader in advanced containment solutions, today announced the opening of a new office...
BATON ROUGE, La., July 29, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and six-month periods ended June 30, 2025.
MONTREAL, July 25, 2025 /CNW/ - Birks Group Inc. (the "Company" or "Birks Group") (NYSE American: BGI), today reported its financial results for the...
NEW YORK, July 25, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global data center infrastructure market is...
NEW YORK, July 25, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global data center infrastructure market is...
JEFFERSONVILLE, Ind., July 24, 2025 (GLOBE NEWSWIRE) -- First Savings Financial Group, Inc. (NASDAQ: FSFG - news) (the "Company"), the holding company for First Savings Bank (the "Bank"), today reported net income of $6.2 million, or $0.88 per diluted share, for the quarter ended June 30, 2025, compared to net income of $4.1 million, or $0.60 per diluted share, for the quarter ended June 30, 2024. Excluding nonrecurring items, the Company reported net income of $5.7 million (non-GAAP measure)(1) and net income per diluted share of $0.81 (non-GAAP measure)(1) for the quarter ended June 30, 2025 compared to $3.5 million, or $0.52 per diluted share for the quarter ended June 30, 2024.
CALHOUN, Ga., July 24, 2025 (GLOBE NEWSWIRE) -- Mohawk Industries, Inc. (NYSE: MHK) today announced second quarter 2025 net earnings of $147 million and earnings per share (“EPS”) of $2.34; adjusted net earnings were $173 million, and adjusted EPS was $2.77. Net sales for the second quarter of 2025 were $2.8 billion, essentially flat as reported and a decrease of 0.8% adjusted for constant days and exchange rates versus the prior year. During the second quarter of 2024, the Company reported net sales of $2.8 billion, net earnings of $157 million and earnings per share of $2.46; adjusted net earnings were $192 million, and adjusted EPS was $3.00.
PARIS, FRANCE, 24 July 2025 - Ipsen announced today that the European Commission has approved Cabometyx® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated pancreatic (pNET) and extra-pancreatic (epNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues.
Early data from robust Autonomy Phase 2b posdinemab trial demonstrate Company's leadership in multimodal biomarkers and early detection
New findings highlight the central role of...
DOWNERS GROVE, Ill., July 24, 2025 /PRNewswire/ -- Dover (NYSE: DOV), a diversified global manufacturer, announced its financial results for the second quarter ended...
Record Second Quarter Revenue Up 15% Year Over Year
Profitability at High End of Guidance
Robust Growth in Service Provider and Enterprise Markets
PLANO, Texas, July...
Five Nuclear Companies to Present at EnerCom Denver – The Energy Investment Conference
Qualified Investors, Analysts and Energy Industry Professionals Can Register at No...
PARIS, FRANCE, 23 July 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care biopharmaceutical company, today announced the following changes to its Executive Committee: